Moreover, given the benefits of canakinumab seen in the CANTOS trial [44], along with the present findings, IL-1β blocker and 1α,25(OH)2D3 might complete each other to attenuate metaflammation in adipose tissue, thus to potentially help prevent metabolic syndrome and subsequent cardiovascular disease. The gene discussed is IL1B; the disease is metabolic syndrome.